


10/568467

1AP20 Rec'd PCT/PTO 14 FEB 2006

"Express Mail" mailing label number	EV 393129601 US
Date of Deposit	February 14, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Queen Thomas	
Printed Name	Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : HEIMAN, Mark L., et al.)
)
National Phase)
of PCT Serial No. : PCT/US2004/025604)
)
International)
Filing Date : September 2, 2004)
)
For : ANTI-GHRELIN ANTIBODIES)
)
Docket No. : X-16339)
)
Customer No. : 25885)

INFORMATION DISCLOSURE STATEMENT SUBMITTED

SIMULTANEOUSLY WITH NATIONAL PHASE ENTRY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner. This form is being submitted simultaneously with the U.S. national phase entry for the above-identified PCT application.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

AP20 Res'd PCT/PTO 14 FEB 2006

Applicants request consideration of this information.

Respectfully submitted,

Charles E. Cohen

Charles E. Cohen
Attorney for Applicants
Registration No. 34,565
Phone: 317-433-4983

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

9 February 2006

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X16339	International Serial No PCT/US2004/025604 2101/568467
	First Applicant Mark L. Heiman	
	Filing Date US Nat'l Entry (if applicable)	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			
	AC	US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP 1 197 496	04-17-2002			
	BB	WO 01/87335	11-22-2001			
	BC					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	International Search Report	
	CB	ARIYASU, et al., "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans," <u>Journal of Clinical Endocrinology & Metabolism</u> , vol. 86, no. 10, October 2001, pp. 4753-4758.	
	CC	DATABASE Geneseq Online, August 13, 2001, "Murine anti-PI-3, 4-P2 antibody light chain variable region," XP002322695.	
	CD	DATABASE Geneseq Online, August 13, 2001, "Murine anti-PI-3, 4-P2 Ig light chain CDR1," XP002322696.	
	CE	HOLT, et al., "Domain antibodies: proteins for therapy," <u>Trends in Biotechnology</u> , vol 21, no. 11, November 2003, pp. 484-490.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X16339	International Serial No PCT/US2004/025604 10/568467
	First Applicant Mark L. Heiman	
	Filing Date US Nat'l Entry (if applicable)	Group

NON PATENT LITERATURE DOCUMENTS (cont.)

	CF	HOSODA, et al., "Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue," <u>Biochemical and Biophysical Research Communications</u> , vol. 279, no. 3, December 29, 2000, pp. 909-913.	
	CG	MURAKAMI, N., et al., "Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats, <u>Journal of Endocrinology</u> , vol. 174, no. 2, August 2002, pp. 283-288	
	CH		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.